×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
Respected all! I am relatively new and has worked in lab mostly. I found a case three-way Philadelphia translocation 46,xy, t (3;9;22) (p21;q34;q11.2). He has been prescribed imatinib 400 mg OD and is doing well apparently.
I want to know if he needs to switch to nilotinib, is there any guidelines showing which drug should the patient use?
The MD Anderson published their data in 2004 that assessed the results of imatinib for patients with variant Philadelphia chromosome (El-Zimaity et al, Br J Haematol, 2004:125;187-95). In a multivariate analysis, the variant Ph had no impact in response rate, overall survival or duration of response.
ORIGINAL CASE:
I found a case three-way Philadelphia translocation 46,xy, t (3;9;22) (p21;q34;q11.2). He has been prescribed imatinib 400 mg OD and is doing well apparently.
I want to know if he needs to switch to nilotinib, is there any guidelines showing which drug should the patient use?
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy